Brokerages Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Price Target at $11.50

Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) has been given a consensus rating of "Moderate Buy" by the five brokerages that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $12.80.

Several equities research analysts have recently issued reports on the company. HC Wainwright decreased their target price on Inovio Pharmaceuticals from $12.00 to $5.00 and set a "neutral" rating for the company in a research report on Monday, November 18th. Royal Bank of Canada decreased their price objective on shares of Inovio Pharmaceuticals from $7.00 to $6.00 and set a "sector perform" rating for the company in a report on Friday, November 15th. Oppenheimer dropped their price objective on Inovio Pharmaceuticals from $33.00 to $15.00 and set an "outperform" rating on the stock in a research note on Monday, November 18th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $18.00 price objective on shares of Inovio Pharmaceuticals in a report on Friday.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of INO. Geode Capital Management LLC increased its holdings in shares of Inovio Pharmaceuticals by 6.7% in the 3rd quarter. Geode Capital Management LLC now owns 621,631 shares of the biopharmaceutical company's stock worth $3,594,000 after buying an additional 38,833 shares during the last quarter. Barclays PLC grew its holdings in shares of Inovio Pharmaceuticals by 282.6% in the third quarter. Barclays PLC now owns 34,003 shares of the biopharmaceutical company's stock worth $197,000 after purchasing an additional 25,116 shares during the last quarter. FMR LLC lifted its holdings in Inovio Pharmaceuticals by 370.1% during the 3rd quarter. FMR LLC now owns 27,261 shares of the biopharmaceutical company's stock valued at $158,000 after buying an additional 21,462 shares in the last quarter. State Street Corp boosted its position in Inovio Pharmaceuticals by 11.7% in the 3rd quarter. State Street Corp now owns 490,662 shares of the biopharmaceutical company's stock valued at $2,836,000 after buying an additional 51,414 shares during the period. Finally, Cornercap Investment Counsel Inc. purchased a new position in shares of Inovio Pharmaceuticals during the second quarter worth approximately $184,000. 26.79% of the stock is currently owned by institutional investors.

Inovio Pharmaceuticals Price Performance

Shares of NASDAQ:INO traded down $0.11 during trading on Friday, reaching $1.98. 970,945 shares of the stock were exchanged, compared to its average volume of 1,935,549. Inovio Pharmaceuticals has a 1-year low of $1.74 and a 1-year high of $14.75. The stock has a fifty day moving average of $3.49 and a two-hundred day moving average of $6.15.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.